Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-017-2012-0
Abstract: 13, 17). Despite the lack of PD-L1 expression, we initiated systemic treatment with nivolumab at 3 mg/kg body weight biweekly. The tumor was initially stable in size but progressed in the further disease course (Fig.… read more here.
Keywords: melanoma; mucosal melanoma; treatment; interleukin unresectable ... See more keywords